Therapeutic effects of gel ointments containing tranilast nanoparticles on paw edema in adjuvant-Induced arthritis rats

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 1, 2014, Pages 96-104

  Nagai, Noriaki ^a   Ito, Yoshimasa ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Adjuvant Induced arthritis; Nanoparticle; Nanotechnology; Tranilast; Transdermal therapeutic system

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARBOPOL 934; DOCUSATE SODIUM; METHYLCELLULOSE; NANOPARTICLE; TRANILAST;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; GEL; GEL OINTMENT; IN VITRO STUDY; MALE; NONHUMAN; OINTMENT; PARTICLE SIZE; PAW EDEMA; RAT; SKIN PENETRATION;

ACRYLATES; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BETA-CYCLODEXTRINS; EDEMA; GELS; INFLAMMATION; MALE; METHYLCELLULOSE; NANOPARTICLES; OINTMENTS; ORTHO-AMINOBENZOATES; PARTICLE SIZE; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; SOLUBILITY;

EID: 84892577662     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00630     Document Type: Article

References (52)

1. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum., 35, 729-735 (1992)
2. Bombini G, Canetti C, Rocha FAC, Cunha FQ. Tumour necrosis factor-alpha mediates neutrophil migration to the knee synovial cavity during immune inflammation. Eur. J. Pharmacol., 496, 197- 204 (2004).
3. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res. Ther., 7 (Suppl. 2), S4-S14 (2005).
4. Park CS, Lim H, Han KJ, Baek SH, Sohn HO, Lee DW, Kim YG, Yun HY, Baek KJ, Kwon NS. Inhibition of nitric oxide generation by 23,24-dihydrocucurbitacin D in mouse peritoneal macrophages. J. Pharmacol. Exp. Ther., 309, 705-710 (2004).
5. Park HJ, Lee SH, Son DJ, Oh KW, Kim KH, Song HS, Kim GJ, Oh GT, Yoon DY, Hong JT. Antiarthritic effect of bee venom: Inhibition of inflammation mediator generation by suppression of NF-κB through interaction with the p50 subunit. Arthritis Rheum., 50, 3504-3515 (2004)
6. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med., 51, 207-229 (2000)
7. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol., 19, 163-196 (2001).
8. Hultqvist M, Olofsson P, Gelderman KA, Holmberg J, Holmdahl R. A new arthritis therapy with oxidative burst inducers. PLoS Med., 3, e348 (2006).
9. Escandell JM, Recio MC, Manez S, Giner RM, Cerda-Nicolas M, Rios JL. Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in lewis rats by suppression of tumor necrosis factor-alpha in T lymphocytes and macrophages. J. Pharmacol. Exp. Ther., 320, 581-590 (2007).
10. Pfab T, Hocher B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J. Hypertens., 22, 883-886 (2004)
11. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines andPGE2 from human monocytes-macrophages. Jpn. J. Pharmacol., 60, 85-90 (1992).
12. Shimizu T, Kanai K, Kyo Y, Asano K, Hisamitsu T, Suzaki H. Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro. J. Pharm. Pharmacol., 58, 91-99 (2006)
13. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J. Hypertens., 22, 1007-1015 (2004).
14. Nagate T, Tamura T, Sato F, Kuroda J, Nakayama J, Shibata N. Tranilast suppresses the disease development of the adjuvant- and streptococcal cell wall-induced arthritis in rats. J. Pharmacol. Sci., 105, 48-56 (2007).
15. The Society of Japanese Pharmacopoeia. Tranilast. Japanese Orange Books, No. 12, Yakuji Nippo Ltd., Tokyo, p. 171 (2002).
16. Tamai H, Katoh O, Suzuki S, Fujii K, Aizawa T, Takase S, Kurogane H, Nishikawa H, Sone T, Sakai K, Suzuki T. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT). Am. Heart J., 138, 968-975 (1999).
17. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv. Drug Deliv. Rev., 56, 619-658 (2004)
18. Denet AR, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev., 56, 659-674 (2004)
19. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev., 56, 559-579 (2004).
20. Mitragotri S, Kost J. Low-frequency sonophoresis: A review. Adv. Drug Deliv. Rev., 56, 589-601 (2004)
21. Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev., 56, 603-618 (2004)
22. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug Deliv. Rev., 56, 675-711 (2004)
23. Tomoda K, Watanabe A, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf. B Biointerfaces, 97, 84-89 (2012).
24. Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids Surf. B Biointerfaces, 92, 50-54 (2012).
25. Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf. B Biointerfaces, 88, 706-710 (2011).
26. Tsujimoto H, Hara K, Huang CC, Yokoyama T, Yamamoto H, Takeuchi H, Kawashima Y, Akagi K, Miwa N, Haung CC. Percutaneous absorption study of biodegradable PLGA nano-spheres via human skin biopsies. J. Soc. Powder Technol., 41, 867-875 (2004).
27. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur. J. Pharm. Sci., 39, 256-262 (2010).
28. Franz TJ. Percutaneous absorption on the relevance of in vitro data. J. Invest. Dermatol., 64, 190-195 (1975)
29. Sloan KB, Siver KG, Koch SA. The effect of vehicle on the diffusion of salicylic acid through hairless mouse skin. J. Pharm. Sci., 75, 744-749 (1986).
30. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
31. DeLouise LA. Applications of nanotechnology in dermatology. J. Invest. Dermatol., 132, 964-975 (2012)
32. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 22, 969-976 (2004).
33. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J., 19, 311-330 (2005).
34. Al-Jamal WT, Al-Jamal KT, Tian B, Cakebread A, Halket JM, Kostarelos K. Tumor targeting of functionalized quantum dotliposome hybrids by intravenous administration. Mol. Pharm., 6, 520-530 (2009).
35. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev., 38, 1759-1782 (2009).
36. Debbage P. Targeted drugs and nanomedicine: Present and future. Curr. Pharm. Des., 15, 153-172 (2009)
37. Huang HC, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J. Control. Release, 155, 344-357 (2011)
38. Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA, Nie S. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano, 4, 5887-5896 (2010).
39. Ilbasmiş-Tamer S, Yilmaz S, Banoǧlu E, Deǧim IT. Carbon nanotubes to deliver drug molecules. J. Biomed. Nanotechnol., 6, 20-27 (2010).
40. Juliano R. Nanobiotechnology II~More Concepts and Applications. (Mirkin AC, Niemeyer MC ed.) Chap. 14, NTS Inc., Tokyo, pp. 235-249 (2007).
41. Nishihata T, Kamada A, Sakai K, Takahashi K, Matsumoto K, Shinozaki K, Tabata Y, Keigami M, Miyagi T, Tatsumi N. Percutaneous absorption of diclofenac in rats and humans: Aqueous gel formulation. Int. J. Pharm., 46, 1-7 (1988).
42. Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Fetoh E, Nutan MT. In vitro release, rheological, and stability studies of mefenamic acid coprecipitates in topical formulations. Pharm. Dev. Technol., 16, 497-510 (2011).
43. Okamoto N, Ito Y, Nagai N, Murao T, Takiguchi Y, Kurimoto T, Mimura O. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. J. Oleo Sci., 59, 423-430 (2010)
44. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162 (1997).
45. Muller BW, Brauns U. Solubilization of drugs by modified β-cyclodextrins. Int. J. Pharm., 26, 77-88 (1985)
46. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest. Ophthalmol. Vis. Sci., 37, 1199-1203 (1996).
47. Nagai N, Takeda M, Ito Y, Takeuchi N, Kamei A. Delay in ICR/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-beta-cyclodextrin inclusion complex. Biol. Pharm. Bull., 30, 1529-1534 (2007)
48. Billingham ME. Models of arthritis and the search for anti-arthritic drugs. Pharmacol. Ther., 21, 389-428 (1983)
49. Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y, Goto T. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res., 50, 509-514 (2001).
50. Kato S, Takeuchi K. Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn. J. Pharmacol., 89, 1-6 (2002).
51. Kato S. Changes in ulcerogenic response to non-steroidal anti-inflammatory drugs (NSAIDs) in adjuvant arthritic rats. Yakugaku Zasshi, 121, 743-751 (2001).
52. Shiota N, Kovanen PT, Eklund KK, Shibata N, Shimoura K, Niibayashi T, Shimbori C, Okunishi H. The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice. Br. J. Pharmacol., 159, 626-635 (2010)